Daiichi Sankyo and AstraZeneca are looking at post-Keytruda

Daiichi Sankyo and AstraZeneca (covered by Smith) have announced their collaboration with Summit Therapeutics (covered by Walch) to evaluate the combination of Datroway and ivonescimab in multiple tumor types including lung and breast. This is a swift move after AZ announced its USD2Bn equity investment into Summit to run joint trials of the two companies' cancer drugs earlier this week. DS and AZ plan to begin with a Ph3 for 1L triple negative breast cancer (TNBC), for which Datroway is approved in PD-L1/PD-1 ineligible subpopulation based on Tropion Breast 02. This is a preemptive strategic move to start developing Datroway in the post-Keytruda era. The two companies are currently conducting TL10 in which Datroway is tested in combo with rilvegostomig, AZ's PD-1/TGIT bisAb, for 1L non-squamous NSCLC with PD-L1 high (TPS≥50%) population. Today's announcement reinforces that DS and AZ are looking beyond Keytruda. We see this announcement as a further confirmation for DS and AZ's confid